Skip to main content

December 2014

 

 

academics

 

Clinical research courses

(Business Wire India); Tata Capital, the financial services arm of the Tata Group, as part of its Do Right initiative, concluded a first-of-its-kind Survey to identify the major challenges facing our country today. The “Tata Capital India4India” Survey was conducted online on the website – doright.in & saw voting from more than 5000 respondents across the country. The top five challenges that emerged as the most concerning for the Indian public were Basic Healthcare, Illiteracy, Child Rights, Women Empowerment and Food Scarcity.

Walk in interview for Executive- Production, Purchase, Marketing in Indian Drugs & Pharmaceuticals Limited | B.Pharm, M.Pharm

IDPL is the largest Central Pharma Public Sector Undertaking in India with plants at Rishikesh, Gurgaon & Hyderabad and two Subsidiary Units at Chennai and Muzaffarpur.

Walk in interview for M.Pharm as Project Assistant II in National Institute of Pharmaceutical Education and Research

National Institute of Pharmaceutical Education and Research (NIPER) is the first national level institute in pharmaceutical sciences with a proclaimed objective of becoming a centre of excellence for advanced studies and research in pharmaceutical sciences. The Government of India has declared NIPER as an 'Institute of National Importance'. It is an autonomous body set up under the aegis of Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India.

IP Addendum-2015 to IP-2014 has been released on 28.11.2014 by Sh. Lov Verma, Secretary Health & Family Welfare and Chairman, India Pharmacopoeia Commission in the presence of senior officers of Ministry of Health & Family Welfare and Scientific Staff of IP Commission.

Career as General Manager/ Dy.General Manager in IDPL

IDPL is the largest Central Pharma Public Sector Undertaking in India with plants at Rishikesh, Gurgaon & Hyderabad and two Subsidiary Units at Chennai and Muzaffarpur.

Regulatory Affairs Specialist in Icon Clinical Research

ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. We specialize in the strategic development, management and analysis of programs that support Clinical Development – from compound selection to Phase I - IV clinical studies

International Conferences on Global Trends in Pharmaceutical & Clinical Practices in Teerthanker Mahaveer University

Teerthanker Mahaveer University is a Jain Minority State Private University established by Act No. 30 of 2008 of the Government of Uttar Pradesh and has been approved by University Grants Commission (UGC) under Section 2(f) of UGC Act, 1956. The university is located on National Highway-24 and is barely 144 Kms from National Capital, New Delhi. The University stands committed to the ideals of Lord Mahaveer i.e.

AstraZeneca announced that MOVENTIG® (naloxegol) has been granted Marketing Authorisation by the European Commission (EC) for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). MOVENTIG is the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) to be approved in the European Union (EU).

Harvard Stem Cell Institute (HSCI) researchers have taken what they describe as “the first step toward a pill that can replace the treadmill” for the control of obesity, though that shift, of course, would not provide all of the many benefits of exercise.

(adsbygoogle = window.adsbygoogle || []).push({});

One of the reasons cancer is so deadly is that it can evade attack from the body's immune system, which allows tumors to flourish and spread. Scientists can try to induce the immune system, known as immunotherapy, to go into attack mode to fight cancer and to build long lasting immune resistance to cancer cells. Now, researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard's School of Engineering and Applied Sciences (SEAS) show a non-surgical injection of programmable biomaterial that spontaneously assembles in vivo into a 3D structure could fight and even help prevent cancer and also infectious disease such as HIV. Their findings are reported in Nature Biotechnology.